What Imegen does

Imegen is a Spanish biomedical brand founded in 2009 and headquartered in Paterna, Valencia, specializing in services and products for genetic analysis. Operationally it is part of HEALTH IN CODE SL, a clinical genomics platform formed in 2020 through the combination of four Spanish diagnostics firms (Imegen, Genycell Biotech, Genologica, and Imegen Agro), with Alantra as the controlling private equity sponsor via its Fund III and, since February 2026, a Hayfin Capital Management-led €155 million continuation vehicle with Mérieux Equity Partners as a 20 percent minority investor.

The company combines genetic testing services, bioinformatics analysis, and clinical interpretation across sixteen clinical specialties including cardiology, oncology, neurology, pharmacogenetics, immunology, nephrology, hematology, ophthalmology, dermatology, neuropediatrics, endocrinology, dysmorphology, inborn errors of metabolism, pneumology, and otolaryngology. Its technology stack spans Whole Genome Sequencing, Trio Exome Sequencing on a NovaSeq X Plus (the first installation in Spain), Long-Read PacBio HiFi sequencing on the Revio platform, and Olink Explore proteomics (where the company is the first certified Service Provider in Spain). Core platforms include ClientSite (variant filtering and report downloading) and Data Genomics (study request, panel customization, and report delivery), forming a software layer atop wet-lab services.

Imegen monetizes through five revenue streams: full-service complete genetic studies performed end-to-end in company labs, sequencing kits sold to laboratories for internalization (bundled with bioinformatics software, database access, equipment lending, and advisory support), clinical variant interpretation services performed for external labs, specialized clinical reports produced by expert biologists and physicians, and proteomics services for drug development and clinical research. Distribution is sales-led via direct relationships with healthcare professionals and medical institutions across Spain (Madrid, Valencia, A Coruña, Granada, Málaga), Portugal (Lisbon), and international channel labs in Germany and Portugal; the company reports serving customers in more than 30 countries. Recent strategic priorities target €100 million revenue within five years, supported by international expansion, acquisitions, and continued sequencing capacity investment.

Name

Imegen

Legal name

HEALTH IN CODE SL

Website

https://imegen.es

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Imegen is a Spanish clinical genomics brand within Health in Code SL, providing genetic testing, bioinformatics, and clinical interpretation services across sixteen medical specialties to hospitals, medical institutions, and healthcare professionals in more than 30 countries, with operations based in Paterna, Valencia.

Ownership category

akta.pro rank

Product category

Clinical Genomics Services

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Clinical genetic testing
• Genomic diagnostics services
• DNA sequencing laboratories
• Hereditary disease diagnosis
• Biomedical genetic analysis

Headquarters

HQ city

Paterna

HQ country

Spain

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Complete Genetic Studies: Full-service genetic testing performed entirely in company laboratories, from sample receipt to specialized clinical report generation
2. Sequencing Kits: Sale of sequencing kits for use in customer laboratories, including bioinformatics software, database access, and equipment lending with full advisory support for internalization
3. Variant Interpretation Services: Clinical and molecular interpretation of genetic studies performed by customer centers, determining pathogenicity of each variant according to international guidelines
4. Clinical Reports: Clinical-genetic reports of results from sequencing performed in customer centers, prepared by expert medical specialists and biologists specialized in genetic diagnosis
5. Proteomics Services: Olink Explore proteomics services for drug development projects, clinical research, and basic biological science research

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Imegen is a biomedical company that provides specialized genetic analysis services and products for the diagnosis of hereditary diseases across 16 clinical specialties. The company performs complete genetic studies in its own laboratories from sample receipt to specialized clinical report generation, and also distributes sequencing kits with bioinformatics software, database access, and equipment lending to enable customer laboratories to internalize testing processes. Its offerings include Whole Genome Sequencing, Trio Exome Sequencing, Long-Read PacBio HiFi sequencing, Olink Explore proteomics, and clinical interpretation of variants by in-house medical specialists.

Product overview

Imegen is a brand under Health in Code SL, a Spanish clinical genomics platform. Imegen operates as a specialized sub-brand (Imegen Agro) focused on agricultural genetics. Health in Code offers a comprehensive portfolio including genetic testing services across multiple clinical specialties, sequencing kits for laboratory use, proteomics services via Olink Explore platform, and long-read sequencing through PacBio technology. The company's solutions encompass complete genetic studies, variant interpretation, and clinical reporting across 14 clinical areas including cardiology, oncology, neurology, immunology, and more.

Differentiator

Problem solved

Functional benefit

Brands

• Genycell Biotech: Biotechnology brand under Health in Code umbrella.
• Genologica
• Imegen Agro

Products and services

• Complete Genetic Studies (Estudio completo) Full-service genetic study performed in company laboratories from sample receipt to delivery of a specialized clinical-genetic report, offered to healthcare professionals and medical institutions for diagnosis of hereditary diseases across multiple clinical specialties.
• Sequencing Kits (Kits de análisis) Reagent kits with accompanying bioinformatics software, database access, and equipment lending provided to clinical laboratories that want to perform their own sequencing, together with full advisory support for process internalization.
• Variant Interpretation Services Expert clinical interpretation of genomic variants generated by customer laboratories, classifying pathogenicity according to international guidelines and providing specialized clinical-genetic reports for diagnostic decision-making.
• Whole Genome Sequencing (WGS) Whole genome sequencing delivering the most comprehensive genetic information, available to healthcare professionals and institutions requiring high-resolution genomic analysis for complex cases.
• Trio Exome Sequencing Complete exome sequencing of family trios (proband and both parents) offering the highest diagnostic yield in complex genetic diseases, available to clinical teams managing patients with suspected hereditary conditions.
• Long-Read PacBio HiFi Sequencing (Revio) Long-read sequencing service using Pacific Biosciences Revio HiFi technology to deliver precise, scalable, and simple long-read genomic analysis for clinical and research applications.
• Olink Explore Proteomics Services Large-scale proteomics studies performed on the certified Olink Explore platform for drug development projects, clinical research, and basic biological science research, capturing high-specificity biological information at any scale.
• Imegen Agro Agricultural genetics brand under the Health in Code umbrella, offering genetic solutions for the agricultural sector.

Quantifiable outcome

• More than doubled revenue from €24 million to over €50 million
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core, major, supporting and regional.

• OlinkcoreTechnology or IntegrationHealth in Code is the first certified Service Provider in Spain for the Olink Explore platform, providing proteomics services for drug development, clinical research, and basic biological science studies.
• PacBio (Pacific Biosciences)coreTechnology or IntegrationLong-Read Sequencing partnership utilizing PacBio Revio technology for HiFi sequencing, providing precision, scalability, and simplicity in long-read genomic analysis.
• SEOM (Sociedad Española de Oncología Médica)majorStrategic or Co-development PartnerSEOM provides scientific endorsement for Health in Code's Learning Genomics educational platform, validating the company's educational initiatives in genomics training.
• Fundación ECOsupportingStrategic or Co-development PartnerFundación ECO is a co-initiator of the Learning Genomics educational platform, supporting the company's educational and knowledge-sharing initiatives in clinical genomics.
• Laboratories in Germany and PortugalregionalChannel Partner/ Reseller/ DistributorStrategic laboratory agreements in Germany and Portugal for expanding genetic testing service delivery across European markets.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• BGI Genomics: Chinese-headquartered high-throughput sequencing services provider with European commercial ambitions and aggressive pricing in NIPT and hereditary panels; an emerging threat to Imegen in pan-European clinical sequencing tenders.

Broad incumbents

• QIAGEN Digital Insights: Global molecular diagnostics and bioinformatics provider with clinical interpretation offerings for hereditary disease and oncology; competes with Imegen primarily on the interpretation/bioinformatics layer and through its broader sample-prep and assay portfolio.
• PerkinElmer Genomics: Genomics services arm of diversified life sciences instrument maker offering clinical and research sequencing; overlaps with Imegen in genetic testing and reproductive health but operates as one service within a much broader analytical instrument portfolio.

Direct peers

• Ambry Genetics: US-based clinical genetic testing laboratory acquired by Konica Minolta, offering hereditary cancer, cardiology, and rare-disease panels with deep variant interpretation; product mix and customer type closely mirror Imegen's hereditary and rare-disease focus areas.
• Invitae: Clinical genetic testing laboratory offering hereditary disease, reproductive health, and oncology panels with proprietary bioinformatics; comparable product set to Imegen across the same clinical specialties, though currently navigating a Labcorp acquisition.
• CENTOGENE: Germany-headquartered rare disease diagnostics and clinical genomics laboratory with multiomics testing, variant interpretation, and pharma partnerships; highly comparable business model and end markets to Imegen, particularly in hereditary and rare disease genetics across Europe.
• SOPHiA GENETICS: Switzerland-based clinical genomics analytics platform combining NGS interpretation software with lab partnerships for hereditary disease, oncology, and pharmacogenomics; comparable through its broad specialty panel coverage and emphasis on variant interpretation that mirrors Imegen's services.
• GeneDx (Sema4): US-focused clinical genetics laboratory with whole exome and whole genome sequencing services and bioinformatics interpretation; serves as a benchmark for Imegen's hereditary disease panels and pediatric rare-disease positioning.
• Eurofins Genomics: Global genomics services arm of Eurofins Scientific offering DNA sequencing, genotyping, and bioinformatics services to pharma, academic, and clinical customers; directly comparable as a one-stop clinical genomics service provider across multiple European geographies where Imegen also competes.

Regional players

• Cegat: Germany-based clinical genetic diagnostics laboratory specializing in hereditary disease panels using NGS; comparable specialty mix to Imegen but concentrated in the German market where Health in Code already has strategic partner laboratories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/imegentw
• Facebookfacebook.com/imegen
• LinkedInlinkedin.com/company/instituto-de-medicina-genomica

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imegen